EXAS: EXACT Sciences Corp.
About
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Current Value
$54.141 Year Return
Current Value
$54.141 Year Return
Key Details
Market Cap
$9.98B
P/E Ratio
-46.01
1Y Stock Return
-17.22%
1Y Revenue Growth
11.91%
Dividend Yield
0.00%
Price to Book
3.1
Strategies that include EXAS
Stock's related to EXAS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LH | 38.01% | $19.76B | +11.24% | 0.91% |
| TRN | 37.40% | $3.12B | +54.58% | 2.95% |
| AMWL | 35.29% | $121.95M | -67.11% | 0.00% |
| ACIW | 34.87% | $5.71B | +106.64% | 0.00% |
| NOVA | 34.56% | $429.84M | -67.33% | 0.00% |
| BGS | 33.37% | $503.48M | -32.20% | 12.01% |
| HWKN | 33.27% | $2.64B | +103.94% | 0.54% |
| AES | 33.19% | $9.78B | -17.86% | 5.04% |
| TTEK | 32.88% | $10.90B | +23.97% | 2.70% |
| RUN | 32.84% | $2.18B | -16.08% | 0.00% |
| DRVN | 32.16% | $2.68B | +26.39% | 0.00% |
| BDC | 31.77% | $4.79B | +72.83% | 0.17% |
| CWEN | 31.49% | $3.26B | +22.27% | 5.84% |
| ARW | 31.45% | $5.98B | -5.69% | 0.00% |
| CWEN.A | 31.30% | $3.07B | +23.13% | 6.22% |
| BV | 30.83% | $1.50B | +115.85% | 0.00% |
| LAD | 30.61% | $9.87B | +38.08% | 0.56% |
| CWAN | 30.57% | $6.77B | +47.68% | 0.00% |
| OMCL | 30.36% | $1.96B | +30.61% | 0.00% |
| OLO | 30.20% | $1.06B | +30.00% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CG | <0.01% | $18.29B | +59.36% | 3.41% |
| EDSA | -0.03% | $7.11M | -21.79% | 0.00% |
| FROG | 0.03% | $3.34B | +11.67% | 0.00% |
| HTHT | 0.05% | $11.34B | -0.47% | 0.00% |
| GGG | 0.06% | $14.83B | +9.01% | 1.16% |
| WCC | -0.08% | $10.02B | +34.53% | 0.79% |
| J | -0.10% | $16.59B | +27.85% | 0.86% |
| SITM | 0.11% | $4.87B | +81.01% | 0.00% |
| TNK | 0.14% | $1.48B | -12.01% | 2.31% |
| COUR | 0.15% | $1.08B | -64.26% | 0.00% |
| ACDC | -0.17% | $1.08B | -17.28% | 0.00% |
| CIEN | 0.19% | $9.69B | +47.41% | 0.00% |
| SDHC | 0.20% | $1.55B | +43.57% | 0.00% |
| DELL | 0.28% | $99.00B | +84.60% | 1.24% |
| KNX | 0.32% | $9.15B | +9.37% | 1.10% |
| OBDE | 0.33% | $1.82B | -2.27% | 4.76% |
| MCS | 0.33% | $669.85M | +49.35% | 1.28% |
| LU | 0.35% | $2.01B | -33.75% | 0.00% |
| GAN | -0.36% | $83.39M | +21.19% | 0.00% |
| FCN | 0.40% | $7.10B | -10.74% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GEO | -29.74% | $3.97B | +204.07% | 0.00% |
| TS | -27.33% | $20.74B | +8.26% | 4.72% |
| EIG | -25.86% | $1.30B | +38.83% | 2.25% |
| LOPE | -23.42% | $4.70B | +18.15% | 0.00% |
| MYRG | -23.36% | $2.35B | +19.41% | 0.00% |
| NUE | -23.31% | $33.97B | -8.31% | 1.48% |
| SAFT | -23.14% | $1.25B | +10.17% | 4.36% |
| STLD | -22.62% | $21.35B | +24.48% | 1.28% |
| WFC | -21.99% | $244.48B | +72.37% | 2.04% |
| CXW | -21.24% | $2.43B | +62.08% | 0.00% |
| QLYS | -21.24% | $5.18B | -21.75% | 0.00% |
| MKL | -20.73% | $21.48B | +16.38% | 0.00% |
| LPLA | -20.73% | $23.55B | +38.13% | 0.38% |
| EG | -19.73% | $15.92B | -8.98% | 2.02% |
| BKR | -19.35% | $42.42B | +26.42% | 1.96% |
| PTVE | -18.92% | $2.25B | +12.14% | 3.19% |
| BRK.B | -18.81% | $1.01T | +29.88% | 0.00% |
| AME | -18.77% | $44.75B | +24.49% | 0.56% |
| WBS | -18.76% | $10.28B | +38.44% | 2.67% |
| AMP | -18.65% | $54.58B | +61.67% | 1.03% |
ETF's related to EXAS
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ICLN | 31.95% | $1.69B | 0.41% |
| FBT | 31.78% | $1.11B | 0.56% |
| PBE | 31.76% | $258.53M | 0.58% |
| PBD | 31.62% | $89.54M | 0.75% |
| XBI | 31.46% | $6.58B | 0.35% |
| TAN | 30.63% | $864.71M | 0.67% |
| ACES | 30.29% | $124.79M | 0.55% |
| IBB | 30.11% | $6.66B | 0.45% |
| REM | 29.93% | $632.41M | 0.48% |
| MORT | 29.92% | $293.96M | 0.43% |
| SCHM | 29.40% | $11.59B | 0.04% |
| FAN | 29.32% | $163.64M | 0.6% |
| NUSC | 29.24% | $1.27B | 0.31% |
| PFUT | 29.21% | $326.69M | 0.64% |
| FHLC | 28.98% | $2.73B | 0.084% |
| QQQJ | 28.91% | $698.04M | 0.15% |
| AOK | 28.91% | $617.23M | 0.15% |
| FALN | 28.87% | $1.84B | 0.25% |
| NUHY | 28.82% | $89.47M | 0.31% |
| FIW | 28.80% | $1.86B | 0.53% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| WEAT | -0.03% | $120.27M | 0.28% |
| CSHI | -0.18% | $482.85M | 0.38% |
| TAIL | 0.27% | $67.98M | 0.59% |
| UNG | -0.53% | $908.80M | 1.06% |
| CLOI | 0.58% | $715.40M | 0.4% |
| HIGH | -0.66% | $302.78M | 0.51% |
| AMDY | 0.77% | $144.24M | 0.99% |
| BITO | 0.93% | $2.65B | 0.95% |
| GBIL | 1.14% | $5.60B | 0.12% |
| FLOT | -1.25% | $7.31B | 0.15% |
| CANE | 1.30% | $17.72M | 0.29% |
| TBIL | -1.31% | $4.38B | 0.15% |
| XBIL | 1.41% | $637.70M | 0.15% |
| CCOR | 1.43% | $109.04M | 1.18% |
| BTF | 1.45% | $51.69M | 1.24% |
| FTGC | 1.49% | $2.17B | 1.02% |
| CORN | 1.54% | $61.12M | 0.2% |
| GSG | 1.72% | $914.42M | 0.75% |
| TPMN | 1.75% | $40.60M | 0.65% |
| SGOV | -1.82% | $27.53B | 0.09% |
News
Yahoo
We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics […]
SeekingAlpha
Exact Sciences Corporation (NASDAQ:EXAS) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ETCompany ParticipantsKevin Conroy - Chairman and...
SeekingAlpha
For Q3 2024, the Fidelity Select Health Care Portfolio fund gained 9.48%, outperforming the MSCI sector index. Click here to read the full commentary.
Yahoo
Exact Sciences presents new positive evidence backing the development of an MCED test.
Yahoo
Those following along with Exact Sciences Corporation ( NASDAQ:EXAS ) will no doubt be intrigued by the recent purchase...
Yahoo
New analysis from the DETECT-A study supports MCED testing as a complement to current guideline-recommended screening in lung cancer.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.